NCT06932744View on ClinicalTrials.gov

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Interventions
DRUG

MY008211A tablets

Participants will receive MY008211A at a dose of 400 mg orally b.i.d for 24 weeks

DRUG

Eculizumab Injection

Eculizumab Injection for 24 weeks

Trial Locations (2)

100032

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

300020

RECRUITING

Chinese Academy of Medical Sciences Hematology Hospital, Tianjin

All Listed Sponsors
lead

Wuhan Createrna Science and Technology Co., Ltd

INDUSTRY